Search research articles
Contact Us
Filters
Showing results (221-230 of 414) with videos related to
Page
of 42
Sort By:
Experimental Biology and Medicine (Maywood, N.J.)
|
January 16, 2009
Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis
Allison B Reiss, David W Wan, Kamran Anwar, et al.
Rheumatology (Oxford, England)
|
February 6, 2021
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus
Daniel J Wallace, David A Isenberg, Eric F Morand, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
February 8, 2014
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study
Richard Furie, Kathy Nicholls, Tien-Tsai Cheng, et al.
Journal of Autoimmunity
|
February 7, 2012
Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity
Amr H Sawalha, Lu Wang, Ajay Nadig, et al.
ACR Open Rheumatology
|
September 15, 2023
Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies
Matthew Studham, Cristina Vazquez-Mateo, Eileen Samy, et al.
The Lancet. Rheumatology
|
November 25, 2024
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial
Anca D Askanase, David D'Cruz, Kenneth Kalunian, et al.
Arthritis Research & Therapy
|
September 13, 2008
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
Richard Furie, William Stohl, Ellen M Ginzler, et al.
Arthritis and Rheumatism
|
July 19, 2002
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial
Michelle A Petri, Robert G Lahita, Ronald F Van Vollenhoven, et al.
Journal of the American Academy of Dermatology
|
October 26, 2024
Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trial
Victoria P Werth, Joan T Merrill, Richard Furie, et al.
Scientific Reports
|
November 21, 2019
Author Correction: Immunologic findings precede rapid lupus flare after transient steroid therapy
Rufei Lu, Joel M Guthridge, Hua Chen, et al.
Page
of 42
Search research articles
Search
Showing results (221-230 of 414) with videos related to
Sort By:
Page
of 42
Experimental Biology and Medicine (Maywood, N.J.)
|
January 16, 2009
Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis
Allison B Reiss, David W Wan, Kamran Anwar, et al.
Rheumatology (Oxford, England)
|
February 6, 2021
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus
Daniel J Wallace, David A Isenberg, Eric F Morand, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
February 8, 2014
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study
Richard Furie, Kathy Nicholls, Tien-Tsai Cheng, et al.
Journal of Autoimmunity
|
February 7, 2012
Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity
Amr H Sawalha, Lu Wang, Ajay Nadig, et al.
ACR Open Rheumatology
|
September 15, 2023
Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies
Matthew Studham, Cristina Vazquez-Mateo, Eileen Samy, et al.
The Lancet. Rheumatology
|
November 25, 2024
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial
Anca D Askanase, David D'Cruz, Kenneth Kalunian, et al.
Arthritis Research & Therapy
|
September 13, 2008
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
Richard Furie, William Stohl, Ellen M Ginzler, et al.
Arthritis and Rheumatism
|
July 19, 2002
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial
Michelle A Petri, Robert G Lahita, Ronald F Van Vollenhoven, et al.
Journal of the American Academy of Dermatology
|
October 26, 2024
Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trial
Victoria P Werth, Joan T Merrill, Richard Furie, et al.
Scientific Reports
|
November 21, 2019
Author Correction: Immunologic findings precede rapid lupus flare after transient steroid therapy
Rufei Lu, Joel M Guthridge, Hua Chen, et al.
Page
of 42